Lawmakers often contend that lobbying, campaign contributions and fancy parties do not sway their votes, yet at least one company begs to differ. As The Washington Examiner reports, Pfizer based its recent decision to grant CEO Jeff Kindler a raise, at least in part, on his "developing and advancing U.S. and global public policies that serve the overall interests of our Company and our shareholders."
The language, buried in the company's most recent proxy statement filed with the Securities and Exchange Commission, explicitly cites Kindler's efforts in "opposing legislation that would allow for importation of prescription drugs."
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.